Syndicated Content about Biotechnology, Pharmaceutical and Healthcare

11:25 EDT 22nd September 2017 | BioPortfolio

Latest global life science, pharmaceutical and healthcare news syndicated from over 50 publishers. 

Showing News Articles 1–25 of 570,000+

Friday 22nd September 2017

Migraine market set to grow to $8.7 billion by 2026; report

Sales of migraine products are expected to grow to $8.7 billion by 2026, at a compound annual growth…

In situ protein detection with enhanced specificity using DNA-conjugated antibodies and proximity ligation

Gastric cancer’s Japanese death toll makes latest Opdivo nod a big one

With the leading pair of immuno-oncology (I-O) agents Keytruda (pembrolizumab) and Opdivo (nivolumab)…

UCB receives EU approval for paediatric anti-epileptic drug

Jellyfish Caught Snoozing Give Clues to Origin of Sleep

The brainless marine creatures are the simplest organisms known to seek slumber -- Read more on

Editorial Board: Biotechnology Journal 9/2017

Inside Cover Picture: Biotechnology Journal 9/2017

The cover art depicts the enzymatic degradation of a dye loaded polymer film which results in a gradual release of the dye. The current work proposes a novel time temperature indicator (TTI) architecture based on this dye release process. TTIs are smart devices that can respond to integrated variations in time and temperature of the surroundings. This is reported by Preetam Anbukarasu, Dominic Sau...

Cover Picture: Biotechnology Journal 9/2017

A new implantable 3D printed device has been fabricated with polylactic acid (PLA) to house pancreatic islets graft. The structure of the device and the addition of an angiogenic matrix within the scaffold have been designed to permit a rapid and mature vasculature to the encapsulation system before cell implantation. Human pancreatic islet loading resulted in a sustained insulin secretion for mon...

Undeclared Drug Leads to Recall of Natural Male Enhancement Supplement

NewsNature Supplement Inc. issues voluntary Florida recall of Vegetable Vigra due to undeclared Sildenafil. Contributed Author: 

Pro-Trader Daily: Corporate News Blog - Eagle Pharma's Licenses Japanese Rights to SymBio Pharma for Bendamustine HCl Ready-to-dilute and Rapid Infusion Injection Products

LONDON, UK / ACCESSWIRE / September 22, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Woodcliff Lake-based Eagle Pharmaceuticals, Inc. (NASDA...

Intercept down 25% after FDA warns on Ocaliva death risk

USA-based Intercept Pharmaceuticals closed 25% down at $73.70 at the end of trading on Thursday.

Sisram Medical, Majority-Owned by Fosun, Stages $125 Million Hong Kong IPO

Sisram Medical, an Israeli aesthetic laser company, completed a $125 million IPO in Hong Kong at the low end of the range. Sisram is majority owned (66%) by Fosun Pharma. Because retail investors were especially interested in the offering, their allocation was increased to 30% of the offering, up from a planned 10%. Sisram, whose stock price has traded steady to slightly lower since the offering, ...

EU allows use of UCB’s anti-epileptic Vimpat in children

The European Commission has ruled that UCB’s anti-epileptic Vimpat can be used in children.

NICE nod for new Eylea indication

The National Institute for Health and Care Excellence (NICE) has issued a final positive recommendation for Bayer’s Eylea as a treatment for adults for the treatment of visual impairment due to myopic chorodial neovascularisation.

TLR agonists suppress tumour growth

Sanofi’s Kevzara will be funded for NHS use

Some patients with rheumatoid arthritis living in England and Wales should get ‘routine’ NHS access to Sanofi’s Kevzara after cost regulators issued draft guidelines deeming the drug cost effective.

Pro-Trader Daily: Corporate News Blog - Novartis Receives EC's Approval for Rydapt; Set to Treat FLT3-Mutated Active Myeloid Leukemia

LONDON, UK / ACCESSWIRE / September 22, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Novartis AG (NYSE: NVS), following which we have publis...

Adult ADHD Treatment Meets Phase 3 Primary Endpoint

NewsShire and Shionogi announce positive topline results for Intuniv evaluated in Phase 3 clinical trial in adults with ADHD. Results also showed improvement over placebo in patients' global functioning.

FDA warning on Intercept’s Ocaliva after patient deaths

US regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals' Ocaliva in patients with primary biliary cholangitis.

Lack of Awareness Limiting Use of Patient Services

NewsNew research from Accenture finds healthcare professionals’ lack of awareness is limiting the usage of patient services offered by pharmaceutical companies.

FDA issues warning on Ocaliva death threat

The US Food and Drug Administration (FDA) is warning that the liver disease drug Ocaliva (obeticholic…

Findings Offers Hope to People With Fibromyalgia

NewsA novel psychological therapy that encourages addressing emotional experiences related to trauma, conflict and relationship problems has been found helpful for people with fibromyalgia.

High Gene-Therapy Costs Trigger Call for New Payment Models

The six-figure prices of new gene therapies will require payers, pharma companies, policymakers, and pharmacy benefit managers (PBMs) to develop new payment models that ensure patient access while reflecting the value delivered by the new treatments based on clinical outcomes, a top executive with PBM Express Scripts asserts. “Gene therapies will require payment and patient care systems that...

Poison Frogs Evolved Poison Resistance via Complementary Mutations

Brightly colored but capable of dark deeds, poison frogs have evolved several ways to accumulate toxic chemicals that are harmful to predators, or the merely curious, while being harmless to the frogs themselves. For example, many poison frogs evolve resistance to their toxins by swapping out amino acids in their neurotransmitter receptors. Thus modified, the receptors become less sensitive to the...

Research identifies potential target for treating inflammatory skin diseases

Targeting Ripk1 could be an effective treatment for skin conditions such as eczema and psoriasis, a study finds.

Quick Search